Bisbenzylisoquinoline alkaloids: animal studies.
Castranova-V; Ma-JK; Ma-JY
Silica and silica-induced lung diseases. Castranova V, Vallyathan V, Wallace WE, eds. Boca Raton, FL: CRC Press, 1995 Dec; :305-321
Current animal and cellular data concerning the biological activities of tetrandrine as they relate to the antifibrotic properties of this drug were reviewed. This drug, based on a traditional folk medicine, has recently been used in China as an antifibrotic drug. Tetrandrine has been shown to exhibit significant antifibrotic activity in animal models of silicosis. This antifibrotic activity was associated with the ability of tetrandrine to inhibit silica (14808607) induced secretion of cytokines and reactive species from pulmonary phagocytes. Such inhibition has been demonstrated both in-vitro and in-vivo with alveolar macrophages and neutrophils in response to a variety of particulate or soluble stimulants. In addition, tetrandrine directly inhibited the ability of pulmonary fibroblasts to proliferate in response to growth factors. The authors suggest that the antifibrotic activity of tetrandrine may be mediated by decreasing oxidant release from alveolar macrophages, suppressing pulmonary inflammation involving activated leukocytes, and inhibiting fibroblast activity. The net results would be less oxidant induced damage and less fibrosis.
Silicosis; Respiratory-system-disorders; Silica-dusts; Dust-inhalation; Dust-exposure; Mineral-dusts; Medical-treatment; Laboratory-animals; Lung-irritants
Castranova-V; Vallyathan-V; Wallace-WE
Silica and silica-induced lung diseases